CHARM Therapeutics
Charm Therapeutics designs and develops a new generation of small-molecule therapeutics that target the interaction between menin and the KMT2A protein, a key driver of acute myeloid leukemia (AML), using its proprietary AI-powered platform called DragonFold. The company’s lead program is a menin inhibitor optimized to maintain activity against all known clinical resistance mutations while minimizing safety and drug-interaction risks. Charm Therapeutics employs protein-ligand co-folding intelligence to inform molecular design, advancing its pipeline from preclinical stages toward the clinic.
Domain
charmtx.com
Country
United KingdomIndustry
Artificial Intelligence (AI)Employees
11-50
Last Funding
$80.0M
Founded
2020
Tech Stack (20 technologies)
Frequently Asked Questions
What technologies does CHARM Therapeutics use?+
CHARM Therapeutics uses 20 technologies including GDPR Cookie Consent Plugin by Webtoffee, Google Analytics, Google Tag Manager.
What industry is CHARM Therapeutics in?+
CHARM Therapeutics operates in the Artificial Intelligence (AI) industry.
Where is CHARM Therapeutics based?+
CHARM Therapeutics is headquartered in United Kingdom.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026